117,679 Shares in Teladoc Health, Inc. $TDOC Acquired by Havemeyer Place LP

Havemeyer Place LP acquired a new position in shares of Teladoc Health, Inc. (NYSE:TDOC) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 117,679 shares of the health services provider’s stock, valued at approximately $824,000. Havemeyer Place LP owned approximately 0.07% of Teladoc Health as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Teladoc Health by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after acquiring an additional 891,732 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Teladoc Health by 23.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after acquiring an additional 1,325,106 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Teladoc Health by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock worth $29,324,000 after acquiring an additional 18,394 shares in the last quarter. Jupiter Asset Management Ltd. increased its stake in Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after purchasing an additional 2,880,008 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Teladoc Health by 11.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock valued at $17,661,000 after purchasing an additional 227,385 shares in the last quarter. Institutional investors own 76.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TDOC. Deutsche Bank Aktiengesellschaft upgraded shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Tuesday, March 10th. BMO Capital Markets cut their price target on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating on the stock in a research note on Thursday, February 26th. TD Cowen cut their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Barclays cut their price target on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Finally, Citigroup upped their price target on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research note on Tuesday, May 5th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.43.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of Teladoc Health stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the transaction, the chief executive officer owned 364,784 shares in the company, valued at approximately $2,002,664.16. This trade represents a 7.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Carlos Nueno sold 6,196 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the transaction, the insider owned 57,671 shares of the company’s stock, valued at $440,029.73. The trade was a 9.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 67,601 shares of company stock worth $454,750. Corporate insiders own 0.70% of the company’s stock.

Teladoc Health Stock Up 0.2%

TDOC stock opened at $7.07 on Tuesday. The firm’s fifty day simple moving average is $6.23 and its 200-day simple moving average is $6.22. The company has a market capitalization of $1.28 billion, a P/E ratio of -7.28 and a beta of 2.14. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. Teladoc Health, Inc. has a 12 month low of $4.40 and a 12 month high of $9.77.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The business had revenue of $613.85 million for the quarter, compared to analyst estimates of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, equities research analysts forecast that Teladoc Health, Inc. will post -0.92 earnings per share for the current year.

Teladoc Health Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.